AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04040426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
Study NCT04040426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibracol Wound Dressing
Description: Application of Collagen Alginate Dressing
Study NCT03064334 — intervention group
Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: surgical knee joints Arthroplasty
Study NCT03552081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragmented DNA evaluation in blood and semen samples
Description: The objective will be to evaluate the decrease in the percentage of sperm with spermatic DNA fragmentation by the TUNEL technique following the evolution of this rate to 3 months, 6 months and 12 months after cessation of smoking by blood and semen samples.
Study NCT03706586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 30% group
Description: Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
Study NCT01169883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Peer Support
Description: The Coping Peer Support is delivered at weekly group meetings over the 10 week active treatment phase. The Coping Peer Support consists of: group support, coping peer group problem solving, and development and recording of Coping Peer Asthma Messages. More specifically, a social worker facilitates a peer group discussion of barriers to taking their daily inhaled steroids, and ways to overcome these barriers. The social worker also facilitates peer recording of messages by the participants encouraging each other to take their daily inhaled steroid medication.
Study NCT01169883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Doctor Asthma Messages
Description: The attention control group will receive Doctor Asthma Messages delivered during the 10 week active treatment phase. The content and number of these messages will be equivalent to those received by the intervention group. These messages are developed and recorded by an Allergist/Immunologist. The participants in the attention control group will listen to these Doctor Asthma Messages, between their favorite music tracks on their MP3 player, as they go about their day-to-day activities.
Study NCT01169883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Peer Asthma Messages
Description: The Coping Peer Asthma Messages developed and recorded by study participants for each other at the weekly coping peer group meetings will be placed on intervention group participants' MP3 players. These Coping Peer Asthma Messages will be played on their MP3 players, between their favorite music tracks, during the course of their daily routines. This infuses the coping peer support from the coping peer group meetings into the adolescents' daily routines.
Study NCT01169883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Supervision
Description: A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.
Study NCT01169883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Supervision
Description: A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.
Study NCT01169883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Tracks
Description: Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.
Study NCT01169883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Tracks
Description: Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.
Study NCT01591603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 cm
Description: A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy
Study NCT01591603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5 cm
Description: A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
Study NCT02188303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2944876
Description: Administered SC
Study NCT03706586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60% group
Description: Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
Study NCT00120003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: 4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
Study NCT00120003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
Study NCT01586845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voclosporin
Description: Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
Study NCT01586845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: tacrolimus as per labeled dose
Study NCT04004052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection
Study NCT04004052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Study NCT04004052 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation (TENS)
Study NCT02188303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00470821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral melatonin 3mg BID
Description: Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
Study NCT00470821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
Study NCT00368706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: Oral
Study NCT00368706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: oral
Study NCT01106547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125mg
Description: Single dose 60-90 minutes preoperatively
Study NCT01106547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 2 ml
Description: Single dose 60-90 min preoperatively
Study NCT04526184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise with blood flow restriction
Description: Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.
Study NCT03184948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brilliance
Description: The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
Study NCT02243501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
Study NCT00323661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate-adaptive pacemaker: accelerometer
Description: Accelerometer based pacing rate adaptation
Study NCT00323661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacemaker: Closed Loop Stimulation
Description: Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
Study NCT01798303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally
Study NCT01798303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT05707572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
Study NCT05707572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual manipulation
Description: The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
Study NCT02490163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Optia
Description: The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.~Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.~The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
Study NCT04684199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
Study NCT03878654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid
Description: Naturally occurirng bile acid
Study NCT04100486 — intervention group
Intervention type: OTHER
Intervention: Standing-Squatting-Standing Test
Description: The participant will begin by actively standing for one minute, followed by a transition to a squat for one minute, and one last transition to one minute of standing.
Study NCT04100486 — intervention group
Intervention type: OTHER
Intervention: Deep Breathing Test
Description: The participant will be asked to lay down for seven minutes and take long, controlled breaths at a rate within 4 to 10 breaths per minute.
Study NCT04100486 — intervention group
Intervention type: OTHER
Intervention: Cold Pressor Test
Description: The participant will be asked to immerse their hand into ice water (1- 10°C) for up to three minutes, followed by removal of the hand from the bath and continuation for recording for a further three to five minutes. The participant will be informed that he or she can remove his or her hand at any point if there is discomfort.
Study NCT04100486 — intervention group
Intervention type: OTHER
Intervention: Cold Face Test
Description: The cold stimulus will be applied with refrigerated gel-filled compresses places on the forehead and cheeks of the participant for one minute.
Study NCT04100486 — intervention group
Intervention type: OTHER
Intervention: Valsalva Maneuver
Description: The participant will be asked to inhale deeply, pinch his or her nose, close his or her mouth, and forcibly exhale, while bearing down with tight chest and stomach muscles, for approximately 10 to 15 seconds. The sensors will continue recording as the participant recovers to normal breathing over the next one minute.
Study NCT04100486 — intervention group
Intervention type: DEVICE
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: The participant will receive electrical stimulation applied to their ear for five minutes. The threshold for stimulation will be determined before the test begins at a level that may elicit sensation (tickling, vibrating, pricking), but no pain. There is a possibility that the participant will receive sham stimulation, or inactive stimulation, for this test.
Study NCT03112863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bakuchiol
Description: This group will receive bakuchiol
Study NCT03112863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retinol
Description: This group will receive retinol
Study NCT01623362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fluoride acidic dentifrice
Description: 550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.
Study NCT01623362 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: conventional dentifrice
Description: 1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months
Study NCT01623362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neutral pH and low-fluoride dentifrice
Description: 500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
Study NCT03143920 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy-
Description: Hyperbaric oxygen therapy provides 100% medical grade oxygen at 2.4 atmospheres of absolute pressure with a Class A multiple person chamber or Class B single person chamber. Hyperbaric chambers are classified as a Class II medical device and have been FDA cleared.
Study NCT01757886 — intervention group
Intervention type: OTHER
Intervention: Biomarkers to analyze both intracoronary thrombi as blood
Study NCT01348789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair2Go (Mē)
Description: Treatment with Hair2Go (Mē) three times every 2-4 days
Study NCT01493635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: analgesic ladder
Description: Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
Study NCT01493635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analgesic ladder
Description: Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
Study NCT02289963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Alirocumab)
Description: Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
Study NCT02108262 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% weight/volume sodium chloride solution (ie, normal saline)
Study NCT02289963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
Study NCT02289963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT02038621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02038621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Study NCT04684199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02038621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and Capecitabine
Description: Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.
Study NCT02038621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin and Capecitabine
Description: Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.
Study NCT02105103 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek® Insight Insulin Pump
Description: A new insulin pump, the Accu-Chek® Insight insulin pump, will be used by all subjects enrolled in this study. The usability of the Accu-Chek® Insight insulin pump for the intended use has already been investigated in a Human Factor study. The study subjects may encounter the following potential risks of CSII therapy while participating in the study: Possible hypoglycemia; Possible hyperglycemia which might progress to ketosis and DKA; Infusion site reactions (bleeding, bruising, discomfort, pruritus, pain, plaster reactions, inflammation, infection etc.)
Study NCT04029272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg tid for 12 weeks
Study NCT04029272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg tid for 12 weeks
Study NCT03533166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 0.03% Chlorhexidine + 0.05% CPC mouth rinse
Study NCT04029272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 2 MG
Description: Exenatide injection once weekly for 12 weeks
Study NCT04005677 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics are collected.
Description: The serum, plasma, urine, faeces, peripheral blood mononuclear cell (PBMC), exhaled breath condensate and the clinical characteristics including age, sex, smoking status, BMI, address, greening environment and the laboratory tests are collected to to analyze the ctDNA, RNA, protein, metabolites, immune status and their relationships with the tumorigenesis and the gene mutation of lung cancer.
Study NCT03533166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo mouth rinse
Study NCT03490487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional antiepileptic drugs
Description: will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
Study NCT03490487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional antiepileptic drugs
Description: will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
Study NCT02937415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath carbon monoxide
Description: Breath carbon monoxide measurement.
Study NCT03490487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral steroid
Description: will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
Study NCT02937415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breath carbon monoxide
Description: Breath carbon monoxide measurement.
Study NCT02937415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary function tests.
Description: Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
Study NCT02937415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests.
Description: Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
Study NCT02937415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxidative stress and antioxidant status.
Description: Measurement of parameters of oxidative stress and antioxidant status in blood samples.
Study NCT02937415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxidative stress and antioxidant status.
Description: Measurement of parameters of oxidative stress and antioxidant status in blood samples.